When is ivermectin indicated for use?

When to Use Ivermectin

Ivermectin should be used for FDA-approved parasitic infections—specifically onchocerciasis and strongyloidiasis—and is also effective for scabies, lymphatic filariasis, and other helminthic infections, but should NOT be used for COVID-19 treatment. 1

FDA-Approved Indications

Onchocerciasis (River Blindness)

• Dosing: 150 mcg/kg as a single oral dose 1
• Mechanism: Kills microfilariae (larval stage) but NOT adult worms, requiring repeated treatment 1
• Efficacy: Reduces skin microfilariae by 83.2% at 3 days and 99.5% at 3 months, with >90% reduction maintained for 12 months 1
• Follow-up: Requires repeated dosing and monitoring since adult parasites survive

Strongyloidiasis (Intestinal Threadworm)

• Dosing: 200 mcg/kg as a single oral dose 1
• Efficacy: Cure rates of 64-100% in clinical trials 1
• Critical follow-up: At least three stool examinations over 3 months post-treatment using concentration techniques (Baermann apparatus), as larvae counts may be very low 1
• Retreatment: If larvae recur (can happen up to 106 days post-treatment), repeat ivermectin 1
• Immunocompromised patients: May require multiple treatment courses at 2-week intervals; cure may not be achievable, and monthly suppressive therapy may be needed 1

Evidence-Based Off-Label Uses

Scabies

• Dosing: 200 mcg/kg, with systematic second dose 2, 3
• Timing: Second dose should be given within 10 days (ideally 7 days apart) for optimal efficacy 2, 3
• Efficacy: 85% healing rate when dose >200 mcg/kg and interval <10 days 2
• Single-dose regimen: Only 58% success rate vs. 98% with two-dose regimen 3
• Pediatric use: Safe in children <15 kg (mean dose 223 mcg/kg), with only 4% mild adverse events 2

Lymphatic Filariasis

• Dosing: 400 mcg/kg (higher than other indications) 4
• Note: Higher doses associated with increased ocular adverse events 4

Other Parasitic Infections

• Enterobiasis: 150-200 mcg/kg 4
• Cutaneous larva migrans, ascariasis, head lice: Emerging evidence 5
• Papulopustular rosacea: Topical 1% cream formulation (different from oral) 6

Critical Contraindications and Warnings

Loiasis Co-infection (ABSOLUTE CONTRAINDICATION in hyperinfection)

• Risk: Patients heavily infected with Loa loa may develop fatal encephalopathy 1
• Geographic risk: West or Central Africa exposure 1
• Threshold: Microfilarial load >8000 mf/mL (especially >30,000 mf/mL) poses severe risk 7, 8
• Management: Pretreatment assessment for loiasis and careful post-treatment monitoring required 1

Pregnancy

• Category C: Teratogenic in animals (cleft palate, clubbed forepaws) 1
• Recommendation: Do NOT use during pregnancy 1

Nursing Mothers

• Excretion: Present in breast milk at low concentrations 1
• Decision: Only treat if risk of delayed maternal treatment outweighs newborn risk 1

Hyperreactive Onchodermatitis (Sowda)

• Risk: More likely to experience severe reactions, especially edema and worsening dermatitis 1

COVID-19: Strong Recommendation AGAINST Use

The IDSA provides a strong recommendation against ivermectin for ambulatory COVID-19 patients and suggests against it for hospitalized patients. 9

• Ambulatory patients: Strong recommendation against (moderate certainty evidence) 9
• Hospitalized patients: Conditional recommendation against (very low certainty evidence) 9
• Rationale: No proven therapeutic utility; in vitro concentrations required far exceed achievable human plasma/lung tissue levels 9
• Meta-analysis evidence: No reduction in mortality (RR 0.88-0.94), hospitalization (RR 0.81), or adverse events for COVID-19 10, 11
• WHO guidance: Recommends against use regardless of illness severity 12

Administration Guidelines

Dosing Principles

• Take on empty stomach with water for optimal absorption 1
• Weight-based dosing: 150-200 mcg/kg for most indications; 400 mcg/kg for lymphatic filariasis 1, 4
• Pediatric <15 kg: Safe and effective at 200-223 mcg/kg 2

Drug Interactions

• Warfarin: Rare reports of increased INR; monitor closely 1
• CYP3A4: Primary metabolic pathway; potential for interactions with strong CYP3A4 inhibitors/inducers 1

Common Pitfalls to Avoid

1. Single-dose scabies treatment: Leads to 42% failure rate; always give second dose at 7-10 days 3
2. Inadequate strongyloidiasis follow-up: Must perform three stool exams over 3 months using concentration techniques 1
3. Assuming adult worm kill in onchocerciasis: Ivermectin only kills microfilariae, not adults; repeated treatment mandatory 1
4. Ignoring Loa loa co-infection risk: Can be fatal; always assess exposure history to endemic areas 1
5. Using for COVID-19: No benefit demonstrated; diverts resources from effective treatments 9, 12
6. Pregnancy use: Teratogenic in animals; avoid unless no alternative exists 1